Login to Your Account

Competitive Landscape

Companies Jockey for Position in Crowded Hepatitis C Market

By Peter Winter

Monday, July 16, 2012

The "blockbuster" drug model may still have some life in it yet. That's what a number of big pharma and "blue chip" biotechs are hoping anyway as they invest millions of research dollars in their quests to develop the next generation of hepatitis C virus (HCV) drugs. The potential market for HCV drugs is predicted to grow rapidly in the next five years and could get even get bigger following recent draft guidelines from the Centers for Disease Control and Prevention (CDC) proposing that all U.S. baby boomers get a one-time test for the hepatitis C virus.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription